At 8.3% CAGR, Middle East & Africa Embolization Devices Market is Projected to be Worth US$ 162.93 Million by 2031, Says Business Market Insights

According to Business Market Insights' research, the Middle East & Africa embolization devices market was valued at US$ 93.26 million in 2024 and is expected to reach US$ 162.93 million by 2031, registering a CAGR of 8.3% from 2025 to 2031. Transforming embolization through clinical innovation and transforming embolization through clinical innovation are among the critical factors attributed to the Middle East & Africa embolization devices market expansion.

Innovations such as improved catheter designs, new embolic agents, and detachable coils have enhanced the efficacy and safety of embolization procedures. For example, the development of flow-diverting devices has revolutionized the treatment of complex intracranial aneurysms by redirecting blood flow away from the aneurysm sac, promoting thrombosis within the aneurysm.

Clinical studies are pivotal in advancing embolization techniques, leading to broader indications and improved patient outcomes. For instance, the IMPASS embolic coil device developed by Fluidx Medical Technology has shown promise in treating chronic subdural hematomas by embolizing the middle meningeal artery (MMA) in January 2023, as demonstrated in in-vivo studies. The Fluidx embolic platform is expected to bring simple preparation and controllable material delivery to various applications.

With the numerous applications for peripheral vascular embolization and the wide range of vessel sizes to be treated, no single agent or device fits all indications. The article titled "Results from the First-in-Human Study of the Caterpillar Arterial Embolization System," published in November 2022, assessed occlusion success and events associated with the use of a self-expanding device for peripheral artery embolization. The study was based on clinical outcomes of the Caterpillar Arterial Embolization Device, which features opposing nitinol fibers and a flow-occluding membrane. The device is designed for use in a broad range of arteries, aiming to reduce the number of devices required to achieve effective occlusion. In this first-in-human trial, the Caterpillar device was successfully deployed to embolize peripheral arteries. The procedure resulted in periprocedural occlusion in all participants and demonstrated a 94.7% rate of freedom from device-related serious adverse events (SAEs) at 30 days. The findings also suggest that the Caterpillar device can be used with minimal risk of SAEs related to the device or procedure.

As the market continues to evolve, the synergy between clinical research and device innovation will be crucial in addressing the growing demand for effective embolization therapies. Therefore, the integration of clinical studies into the development of embolization devices, fostering significant advancements in the field and leading to expanded treatment options and improved patient outcomes, is emerging as a significant trend in the embolization devices market.

On the contrary, complications arising during or after embolization hamper the growth of Middle East & Africa embolization devices market.

Based on type, the Middle East & Africa embolization devices market is segmented into embolization coils, plugs, beads, glues, and others. The embolization coils segment held 60.9% share of the Middle East & Africa embolization devices market in 2024, amassing US$ 56.75 million. It is projected to garner US$ 101.51 million by 2031 to expand at 8.6% CAGR during 2025-2031. The embolization coils segment is further subsegmented into central application and peripheral application.

Based on application, the Middle East & Africa embolization devices market is segmented into neurology, peripheral vascular disease, oncology, urology, and others. The neurology segment held 41.0% share of the Middle East & Africa embolization devices market in 2024, amassing US$ 38.27 million. It is projected to garner US$ 69.39 million by 2031 to expand at 8.8% CAGR during 2025-2031.

Based on end user, the Middle East & Africa embolization devices market is segmented into hospitals, ambulatory centers, and others. The hospitals segment held 56.2% share of the Middle East & Africa embolization devices market in 2024, amassing US$ 52.43 million. It is projected to garner US$ 94.38 million by 2031 to expand at 8.7% CAGR during 2025-2031.

Based on country, the Middle East & Africa embolization devices market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. South Africa held 29.4% share of Middle East & Africa embolization devices market in 2024, amassing US$ 27.40 million. It is projected to garner US$ 48.64 million by 2031 to expand at 8.5% CAGR during 2025-2031.

Key players operating in the embolization devices market are Medtronic Plc; Cook Medical Holdings LLC; Stryker Corp; Boston Scientific Corp; Terumo Corp; Johnson & Johnson; Abbott Laboratories; NeuroSafe Medical Co. Ltd; Wallaby Medical; Sirtex Medical Ltd; GEM srl; Penumbra Inc.; Balt; Lepu Medical Technology Beijing Co Ltd; INVAMED; Meril Life Sciences Pvt Ltd; Merit Medical Systems Inc; and Lifetech Scientific Corp, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com